期刊文献+

pIRES2-MLAA34-EGFP穿梭载体的构建及表达 被引量:1

Construction of p IRES2-MLAA34-EGFP vector and its expression
下载PDF
导出
摘要 目的构建p IRES2-MLAA34-EGFP重组质粒,并对其进行原核诱导表达。方法用RT-PCR的方法从U937细胞中提取MLAA-34基因,利用酶切、T4连接等分子生物学技术将MLAA-34目的基因克隆至p IRES2-EGFP表达载体中,经PCR、酶切等技术对构建的重组表达载体p IRES2-MLAA34-EGFP进行鉴定后,转化大肠杆菌BL21并进行诱导表达。结果扩增出MLAA-34全长基因1 014 bp,构建了p IRES2-MLAA34-EGFP重组质粒,经PCR和双酶切鉴定,与预期大小一致。重组质粒在大肠杆菌中经IPTG诱导和SDS-PAGE检测,所表达的融合蛋白与预期蛋白相符合。结论成功构建了p IRES2-MLAA34-EGFP重组质粒,并使其在大肠杆菌中高效表达。 Objective To construct the pIRES2-MLAA34-EGFP recombinant vector and express the MLAA34-EGFP recombinant proteins in E.coli.Methods The MLAA34 gene were extracted from U937 cells by RT-PCR and insert into the pIRES2-EGFP vector.Results We amplified full-length sequence of MLAA-34 gene successfully and iden-tified the correctness of pIRES2-MLAA34-EGFP recombinant vector by PCR and BamHⅠ/EcoRⅠdouble digestion. Moreover,the MLAA34-EGFP recombinant proteins expressed in E.coli were consistent with the expected protein. Conclusion We construct the pIRES2-MLAA34-EGFP recombinant vector successfully and the MLAA34-EGFP re-combinant proteins was successfully induced to express by IPTG.
出处 《吉林医药学院学报》 2016年第3期184-187,共4页 Journal of Jilin Medical University
基金 吉林省科技厅自然科学基金项目(20160101179JC) 吉林省卫生和计划生育委员会项目(2015Z071) 吉林省大学生创新创业课题(2015024)
关键词 急性白血病 MLAA-34 免疫治疗 核酸疫苗 acute leukemia immunotherapy DNA vaccine
  • 相关文献

参考文献12

  • 1Brichard VG, Lejeune D. Cancer immunotherapy tax^etingtumour-specific antigens: towards a new therapy for mini-mal residual disease [ J ]. Expert Opin Biol Ther,2008,8(7):951-968.
  • 2Bross PF, Beitz J, Chen Gang, et al. Approval summary:gemtuzumab ozogamicin in relapsed acute myeloid leukemia[J]. Clin Cancer Res,2001,7(6) : 1490-1496.
  • 3Zhang Long,Gajewski TF,Kline J. PD-1/PD-L1 interactionsinhibit antitumor immune responses in a murine acute mye-loid leukemia model[J] . Blood,2009,114(8) : 1545-1552.
  • 4Peled A,Tavor S. Role of CXCR4 in the pathogenesis of a-cute myeloid leukemia [ J ] . Theranostics,2013,3(1): 34-39.
  • 5Chen Gang,Zhang Wanggang,Cao Xingmei,et al. Serologicalidentification of immunogenic antigens in acute monocyticleukemia[ J] . Leuk Res,2005,29(5) :503-509.
  • 6Zhang Wenjuan,Zhang Wanggang,Zhang Pengyu,et al. Theexpression and functional characterization associated withcell apoptosis and proteomic analysis of the novel geneMLAA-34 in U937 cells[J]. Oncol Rep,2013,29(2) :491-506.
  • 7Zhao Jianqiang,He Aili,Zhang Wanggang,et al. Quantitativeassessment of MLAA-34 expression in diagnosis and progno-sis of acute monocytic leukemia [ J ]. Cancer Immunol Immu-nother,2011,60(4) :587-597.
  • 8王振义,陈秋生.急性白血病免疫治疗的研究现况和前景[J].中国实验血液学杂志,2005,13(2):169-173. 被引量:12
  • 9Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progressand challenges[ J]. J Immunol ,2005,175(2) :633-639.
  • 10Srivastava IK, Liu MA. Gene vaccines [ J ] . Ann InternMed,2003,138(7) :550-559.

二级参考文献28

  • 1王建祥.急性髓系白血病的化疗[A]..第八次全国血液学学术会议论文汇编[C].北京,2004.第31页.
  • 2Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.Expert Opin Biol Ther, 2001; 1: 893 -901.
  • 3Leopold LH, Berger MS, Feingold J. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. Clin Lymphoma, 2002; 2 ( Suppl 1 ): S29- S34.
  • 4Tsimberidou A, Estey F, Cortes J, et al. Gemtuzumab, fiudarabine, cytarbine and cyclosporine in patients with newly newly diagnosed acute myelogenous leukemin or high-risk myelodysplastic syndrome. Cancer, 2003; 97:1481 - 1487.
  • 5LoCoco F, Cimino G, Breccia M, et al. Gentuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 2004; 104: 1995 - 1999.
  • 6Lundin J, Kimby E, Bjorkholm M, et al. Phase Ⅱ trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campth1H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 2002; 100: 768 - 773.
  • 7Hillmen P. Advancing therapy for chronic lymphocytic leukemia -the role of rituximab. Semin Oncol, 2004; 31 (Suppl 2): 22 -26.
  • 8Mourad YA, Taher A, Chehal A, et al. Successful treatment of Bcell prolymphocytic leukemia mith monoclonal anti-CD20 antibody.Ann hematol, 2004; 83:319-321.
  • 9Chen J,Zhou JH, Ball ED. Characterization of a new monoclonal antibody 6G7 that recognizes a unique antigen on myeloid and lymphoid cells. J Hematother & Stem Cell Res, 2001; 10:237 -246.
  • 10Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control, 2002; 9: 106 - 113.

共引文献11

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部